Atipharmed Supports the 6th International Congress on Minimally Invasive Techniques in Gynecology and Endometriosis

Author:
Date:
27 January 2025
4R4A061511-2048x1365

The 6th International Congress on Minimally Invasive Techniques in Gynecology, Obstetrics, and Endometriosis took place from January 23 to 25 at Abureihan Hall, Shahid Beheshti University, with Atipharmed, a subsidiary of Actoverco, as its key sponsor.

According to Actoverco’s Public Relations Department, Atipharmed not only supported the event but also actively participated in its exhibition, where it showcased its latest advancements and pharmaceutical products for gynecology and obstetrics to specialists, physicians, and other attendees.

During the opening ceremony, Dr. Abolfazl Mahdizadeh, Professor at Iran University of Medical Sciences and President of the Congress, remarked, “This congress, organized by the Iranian Association of Minimally Invasive Gynecological Surgery in collaboration with Iran University of Medical Sciences and other scientific associations, aims to promote the adoption and application of the latest minimally invasive surgical and therapeutic techniques in gynecology and obstetrics.”

He further highlighted the importance of these techniques, stating, “Minimally invasive methods have transcended surgical procedures such as laparoscopy and hysteroscopy, becoming an essential approach across all medical fields, particularly in gynecology. These techniques empower women to benefit from early diagnosis, reduced medication, improved surgical outcomes, shorter hospital stays, and lower treatment costs while minimizing pain and discomfort.”

The congress featured an impressive program, including 10 lectures by leading international experts, six keynote speeches by esteemed Iranian professors, 23 specialized panel discussions, and the inaugural Laparoscopic Film Festival. A tribute was also held for Dr. Ashraf Sadat Jamal, the founder of perinatology in Iran, alongside commemorations for pioneers in gynecology and obstetrics, such as Dr. Mohammad Hassan Badakhsh, Dr. Mansour Ashrafinia, and Dr. Seyed Mehdi Ahmadi. The event concluded with a celebratory gala.

Atipharmed, renowned for operating the first GMP-certified pharmaceutical plant in Iran specializing in hormonal medications, presented its comprehensive portfolio of women’s health products at the congress. These products included:

  • Finasteride (Finoscar)
  • Levonorgestrel (Tansy)
  • Medroxyprogesterone Acetate (Progera)
  • Megestrol Acetate (Megera)
  • Clomiphene Citrate (Clophan)
  • Conjugated Estrogens (Prequin)
  • Estradiol Hemihydrate (gynati)
  • Dienogest and Ethinyl Estradiol (Belagest)
  • Oxandrolone
  • Dienogest (Verogest)
  • Drospirenone and Ethinyl Estradiol (Drosbela, Drosbelin)
  • Cyproterone Compound (Sybelle)
  • Progesterone (Actogest)
  • Dydrogesterone (Dofamed)
  • Desogestrel and Ethinyl Estradiol (Desoleste)
  • Letrozole 

By supporting and participating in this prestigious event, Atipharmed underscored its commitment to advancing women’s health and its leadership in the pharmaceutical industry.

Related Posts

4R4A061511-2048x1365

Atipharmed Supports the 6th International Congress on Minimally Invasive Techniques in Gynecology and Endometriosis

M_HA2443

Scientific Conference on the Effects of Hormone Replacement Therapy (HRT) in Menopause

4R4A3160

Holding the 21st MS Congress of Iran with the participation of Actoverco

M_HA1634

Presentation of Actover’s latest products at the Gastrointestinal and Liver Diseases Congress

4R4A2655-Pano

Introduction of Actoverco Cardiovascular Medications at the 8th International Heart Failure Congress